当前位置：
X-MOL 学术
›
BMC Med. Genomics
›
论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
The values of AHCY and CBS promoter methylation on the diagnosis of cerebral infarction in Chinese Han population
BMC Medical Genomics ( IF 2.7 ) Pub Date : 2020-11-02 , DOI: 10.1186/s12920-020-00798-7 Xiaodong Li , Shufang Bu , Ran Ran Pan , Cong Zhou , Kun Qu , Xiuru Ying , Jie Zhong , Jianhao Xiao , Qian Yuan , Simiao Zhang , Laura Tipton , Yunliang Wang , Youping Deng , Shiwei Duan
BMC Medical Genomics ( IF 2.7 ) Pub Date : 2020-11-02 , DOI: 10.1186/s12920-020-00798-7 Xiaodong Li , Shufang Bu , Ran Ran Pan , Cong Zhou , Kun Qu , Xiuru Ying , Jie Zhong , Jianhao Xiao , Qian Yuan , Simiao Zhang , Laura Tipton , Yunliang Wang , Youping Deng , Shiwei Duan
The goal of our study is to investigate whether the methylation levels of AHCY and CBS promoters are related to the risk of cerebral infarction by detecting the methylation level of AHCY and CBS genes. We extracted peripheral venous blood from 152 patients with cerebral infarction and 152 gender- and age-matched healthy controls, and determined methylation levels of AHCY and CBS promoters using quantitative methylation-specific polymerase chain reaction. We used the percentage of methylation reference (PMR) to indicate gene methylation level. We compared the promoter methylation levels of two genes (AHCY and CBS) in peripheral blood DNA between the cerebral infarction case group and the control group. Our study showed no significant difference in AHCY promoter methylation between case and control. Subgroup analysis by gender showed that the methylation level of AHCY in males in the case group was lower than that in the control group, but the difference was not statistically significant in females. In a subgroup analysis by age, there was no significant difference in the AHCY methylation level between the case and control in the young group (≤44 years old). However, the level of AHCY gene methylation in the middle-aged group (45–59 years old) was significantly higher and the aged group (≥60 years old) was significantly lower than that in the control groups. However, CBS promoter methylation levels were significantly lower in the case group than in the control group (median PMR: 70.20% vs 104.10%, P = 3.71E-10). In addition, the CBS methylation levels of males and females in the case group were significantly lower than those in the control group (male: 64.33% vs 105%, P = 2.667E-08; female: 78.05% vs 102.8%, P = 0.003). We also found that the CBS levels in the young (23–44), middle-aged (45–59), and older (60–90) groups were significantly lower than those in the control group (young group: 69.97% vs 114.71%; P = 0.015; middle-aged group: 56.04% vs 91.71%; P = 6.744E-06; older group: 81.6% vs 119.35%; P = 2.644E-04). Our ROC curve analysis of CBS hypomethylation showed an area under the curve of 0.713, a sensitivity of 67.4%, and a specificity of 74.0%. Our study suggests that hypomethylation of the CBS promoter may be closely related to the risk of cerebral infarction and may be used as a non-invasive diagnostic biomarker for cerebral infarction.
更新日期：2020-11-02
京公网安备 11010802027423号